Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT01181258
First received: August 12, 2010
Last updated: January 21, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2015
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)